PTEN and prostate carcinoma: We first investigated how MSeA impacts REDD1, AKT, and p70S6K (downstream target of mTORC1) in three different prostate cancer cell lines, DU145 (PTEN+), PC3, and PC-3M (PTEN−) at 2, 6 h and overnight (18 h) treatments with MSeA in hypoxia.